UNSPSC 51285310: Nifuradene

This classification denotes a topical anti-infective agent with the molecular formula C8H8N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VX65207DR, chemically known as 2-imidazolidinone, 1-(5-nitrofurfurylideneamino)- but more generally known as nifuradene, which bears US NIH Compound Identifier 11154. European Medicines Agency schedules Nifuradene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09258MIG.

UNSPSC 51285310 Nifuradene, a Commodity code, nominally addresses a specific pharmaceutical ingredient, but recent state and local procurement activity under this code does not align with that narrow scope. Instead, the code appears in solicitations for broader pharmaceutical and medical supply categories, including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription programs. State and local buyers under this code span county health departments, state health and human services agencies, municipal fire departments, and cooperative purchasing alliances. The work being solicited includes procurement of finished pharmaceutical products and emergency medical supplies for operational and community health use, quarterly or ongoing supply agreements with delivery obligations, and vendor qualification for manufacturing compliance, insurance requirements, and regulatory certifications including cGMP and DSCSA adherence.

Recent activity spans Florida, Texas, Minnesota, and Oregon, with the most visible solicitations originating from Seminole County, Florida (IFB 60459723LAS for naloxone and drug deactivation systems, due July 26, 2023); the City of Tampa, Florida (IFB 26P00145 for medical and first aid supplies to the Fire Department Rescue Division, posted March 25, 2026, due March 13, 2026, estimated at $700,000, designated as a sheltered Small Local Business Enterprise opportunity with a 5% bid discount capped at $10,000); the Texas Health and Human Services Commission (RFI HHS0017013 for direct-to-manufacturer prescription capabilities, posted April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance (RFP S1070000015802 for generic pharmaceuticals and OTC products, due March 26, 2026, effective July 1, 2026). The Tampa procurement is explicitly set aside for certified SLBEs and includes a minimum outreach contact list. The MMCAP RFP involves multi-state participation and requires vendor relationships with three authorized wholesalers.